Junshi Collaborates With DotBio to Discover Multi-Specific Antibodies
January 07, 2022 at 05:49 AM EST
Shanghai Junshi Bio formed a collaboration with Singapore 's DotBio to develop next-gen antibody therapies. Junshi in-licensed a DotBody module, which it will use to discover several multi-specific antibodies. DotBody's proprietary technology combines prefabricated antibody modules that have specific functions. DotBio says the technology builds multi-functional antibodies quickly, improving antibody quality and increasing their rate of success. DotBio will be receive upfront and milestone payments, as well as royalties. DotBio previously signed a licensing deal with Suzhou 's CStone Pharma. More details.... Stock Symbols: (HK: 1877: SHA: 688180) (HK: 2616) Share this with colleagues:
